Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.56 |
| ▸ | NPC1 | O15118 | 5/20 | 0.56 |
| ▸ | HPGD | P15428 | 4/20 | 0.56 |
| ▸ | RAB9A | P51151 | 4/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23269595 | 0.85 | HDAC3 (0.62) | SMYD3SMN1; SMN2NPC1HPGDRAB9A | |
| SCHEMBL15866466 | 0.81 | NPC1 (0.68) | SMYD3SMN1; SMN2NPC1HPGDRAB9A | |
| SCHEMBL21703565 | 0.81 | HRH3 (0.64) | SMYD3HRH3SMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL25141603 | 0.78 | SMYD3 (0.59) | SMYD3SMN1; SMN2NPC1HPGDRAB9A | |
| SCHEMBL21940956 | 0.77 | HRH3 (0.70) | HRH3ALDH1A1NPSR1 | |
| SCHEMBL14924418 | 0.77 | HRH3 (0.70) | HRH3SMN1; SMN2NPC1HPGDRAB9A | |
| SCHEMBL520877 | 0.77 | NPC1 (0.82) | SMN1; SMN2NPC1HPGDRAB9ACYP1A2 | |
| SCHEMBL28928584 | 0.77 | NPC1 (0.82) | SMN1; SMN2NPC1HPGDRAB9ACYP1A2 | |
| SCHEMBL126657 | 0.77 | NPC1 (0.82) | SMN1; SMN2NPC1HPGDRAB9ACYP1A2 | |
| SCHEMBL24031866 | 0.76 | SMYD3 (0.60) | SMYD3SMN1; SMN2NPC1HPGDRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210147385-A1 | COMPOUNDS AND METHODS FOR TARGETING PATHOGENIC BLOOD VESSELS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147385-A1 | COMPOUNDS AND METHODS FOR TARGETING PATHOGENIC BLOOD VESSELS | TEK, KDR, LIPG | SMYD3 3263/4885HRH3 4015/4885SMN1; SMN2 1703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.